Spyre Therapeutics Enters Material Definitive Agreement

Ticker: SYRE · Form: 8-K · Filed: Oct 15, 2024 · CIK: 1636282

Spyre Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanySpyre Therapeutics, Inc. (SYRE)
Form Type8-K
Filed DateOct 15, 2024
Risk Levelmedium
Pages5
Reading Time6 min
Key Dollar Amounts$0.0001, $22.0 million, $1.5 million, $2.5 million
Sentimentneutral

Sentiment: neutral

Topics: material-definitive-agreement, corporate-action

TL;DR

Spyre Therapeutics just signed a big deal, filing an 8-K on Oct 11.

AI Summary

On October 11, 2024, Spyre Therapeutics, Inc. (formerly Aeglea BioTherapeutics, Inc.) entered into a material definitive agreement. The company, incorporated in Delaware, is involved in the pharmaceutical preparations industry.

Why It Matters

This filing indicates a significant contractual development for Spyre Therapeutics, which could impact its future operations and strategic direction.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, the specifics of which are not detailed in this initial filing.

Key Numbers

  • 001-37722 — Commission File Number (SEC file identifier for Spyre Therapeutics, Inc.)
  • 46-4312787 — IRS Employer Identification No. (Tax identification number for Spyre Therapeutics, Inc.)

Key Players & Entities

  • Spyre Therapeutics, Inc. (company) — Registrant
  • Aeglea BioTherapeutics, Inc. (company) — Former company name
  • October 11, 2024 (date) — Date of earliest event reported
  • Delaware (jurisdiction) — State of incorporation
  • 221 Crescent Street Building 23 Suite 105 (address) — Principal Executive Offices
  • Waltham, MA (location) — City, State of Principal Executive Offices
  • 02453 (zip_code) — Zip code of Principal Executive Offices

FAQ

What type of material definitive agreement did Spyre Therapeutics, Inc. enter into?

The filing states that Spyre Therapeutics, Inc. entered into a 'Material Definitive Agreement' but does not specify the nature of the agreement.

When was the earliest event reported in this 8-K filing?

The earliest event reported was on October 11, 2024.

What was Spyre Therapeutics, Inc. formerly known as?

Spyre Therapeutics, Inc. was formerly known as Aeglea BioTherapeutics, Inc.

In which state is Spyre Therapeutics, Inc. incorporated?

Spyre Therapeutics, Inc. is incorporated in Delaware.

What is the principal executive office address for Spyre Therapeutics, Inc.?

The principal executive office is located at 221 Crescent Street, Building 23, Suite 105, Waltham, MA 02453.

Filing Stats: 1,392 words · 6 min read · ~5 pages · Grade level 13.3 · Accepted 2024-10-15 06:10:08

Key Financial Figures

  • $0.0001 — nge on which registered Common Stock, $0.0001 Par Value Per Share SYRE The Nasdaq
  • $22.0 million — mpany is obligated to pay Paragon up to $22.0 million based on specific development, regulato
  • $1.5 million — t to reach such milestones, including a $1.5 million fee for nomination of a development can
  • $2.5 million — ble, and a further milestone payment of $2.5 million upon the first dosing of a human patien

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 10.1 IL-23 (SPY003) License Agreement, dated October 11, 2024, by and between the Company and Paragon Therapeutics, Inc. 10.2 Amended and Restated Biologics Master Services Agreement, dated October 14, 2024, by and between the Company and WuXi Biologics (Hong Kong) Limited. 10.3 Amended and Restated Cell Line License Agreement, dated October 14, 2024, by and between the Company and WuXi Biologics (Hong Kong) Limited. 99.1 Press Release of the Company, dated October 14, 2024 99.2 Corporate Presentation (October 2024) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SPYRE THERAPEUTICS, INC. Date: October 15, 2024 By: /s/ Cameron Turtle Cameron Turtle Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.